Eli Lilly and Company

Robert Jan Benschop

Barrett Allan

Jirong Lu

Julian Davies

Ryan James Darling

Chetankumar Natvarlal Patel

Stephanie Marie Truhlar

Angela Jeannine Okragly

Mark Geoffrey Chambers

Stephen John Demarest

Xiufeng Wu

Allan Barrett

Lu Jirong

Antibodies which bind and neutralize human IL-33, and methods of using same, are provided, said antibodies are useful as agents for treating conditions associated with allergic disease including treating atopic dermatitis.

DNA molecules encoding anti-IL-33 antibodies

IgG bispecific antibodies are provided that bind human Calcitonin Gene Related Peptide (CGRP) and human Interleukin-23 (IL-23) and are characterized as having high affinity and strong simultaneous neutralizing properties to both human CGRP and human IL-23. The bispecific antibodies of the invention are useful for treating various autoimmune diseases including Inflammatory Bowel Disease, such as Crohn's Disease (CD) and Ulcerative Colitis (UC), and other autoimmune diseases such as psoriatic Arthritis (PsA), ankylosing spondylitis (AS) and atopic dermatitis (AtD). The bispecific antibodies of the invention are useful for treating pain associated with the aforementioned diseases.

Anti-CGRP/anti-IL-23 bispecific antibodies and uses thereof

Anti-IL-33 antibodies and uses thereof for disease treatment

Bispecific antibodies are provided that specifically bind B-cell Activating Factor of the TNF Family (BAFF) and Interleukin-17A (IL-17) and are characterized as having high affinity and strong neutralizing properties to both BAFF and IL-17. The bispecific antibodies of the invention are expected to be useful in treating Lupus Nephritis (LN), Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), Psoriasis (Ps), Ankylosing Spondylitis (AS), Psoriatic Arthritis (PA), primary Sj&#xf6;gren's Syndrome (pSS), or Multiple Myeloma (MM).

Anti-BAFF-anti-IL-17 bispecific antibodies

The present invention provides human engineered calcitonin gene related peptide (CGRP) antibodies or antigen-binding fragment thereof. In addition, the present invention provides the use of the human engineered calcitonin gene related peptide (CGRP) antibodies or antigen-binding fragment thereof for the treatment of osteoarthritis pain.

Method to treat migraines using CGRP antibodies

CGRP antibodies

Growing community of inventors

Indianapolis, IN, United States of America

Robert Jan Benschop